The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety profile and disease stabilization in late stage, heavily pretreated, solid tumor patients in a first-in-human (FIH) study of ATX-101, a drug targeting proliferating cell nuclear antigen (PCNA).
 
Charlotte Rose Lemech
No Relationships to Disclose
 
Ganessan Kichenadasse
No Relationships to Disclose
 
Jens-Peter Marschner
Employment - APICES; Therapim; Zelluna
Stock and Other Ownership Interests - Abbvie; Affimed Therapeutics
 
Kostas Alevizopoulos
Employment - APICES; Therapim
Stock and Other Ownership Interests - TheraPten; Ventac Holding (Cyprus) LTD
Consulting or Advisory Role - Coegin Pharma; Gerolymatos International SA; Ventac Holding (Cyprus) LTD
 
Marit Otterlei
Employment - APICES
Leadership - APICES
Stock and Other Ownership Interests - APICES
 
Michael Millward
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche; Takeda
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Albion Laboratories (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Apollomics (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Dizal Pharma (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MaxiNovel (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Therapim (Inst)
Travel, Accommodations, Expenses - AstraZeneca